What Is Congenital Myotonic Dystrophy?

Congenital myotonic dystrophy is the most severe form of myotonic dystrophy type 1, a genetic muscle disorder that begins before birth and causes life-threatening problems in newborns, including extreme muscle weakness, breathing failure, and feeding difficulties. Unlike the more common adult-onset version of the disease, which typically appears in middle age with gradually worsening muscle stiffness, the congenital form affects babies from the moment they are born and carries a substantial risk of death in the first weeks of life.¹ Babies who survive the newborn period face a long road that includes intellectual disability, ongoing respiratory illness, and challenges that touch nearly every aspect of daily life.

How It Differs from Adult-Onset Myotonic Dystrophy

Myotonic dystrophy type 1 exists on a spectrum. At the mildest end, some people develop cataracts and slight muscle stiffness late in life and never receive a diagnosis. The classic adult form brings progressive muscle wasting, heart rhythm problems, and the hallmark symptom of myotonia, where muscles contract normally but are slow to relax. Congenital myotonic dystrophy sits at the opposite extreme. Babies with the congenital form rarely show myotonia at birth. Instead, their muscles are profoundly floppy, they struggle to breathe on their own, and they often cannot suck or swallow well enough to feed.² The distinction matters because clinicians who are looking for myotonia as a diagnostic clue can easily miss congenital cases entirely.

Another key difference is cognitive involvement. Adults with classic myotonic dystrophy can develop subtle executive-function problems and daytime sleepiness, but their IQ is often in the normal range. In the congenital form, intellectual disability is the norm rather than the exception. A cross-sectional study measuring functional outcomes in people with congenital myotonic dystrophy found a mean IQ of about 66, roughly three standard deviations below average.³ Executive dysfunction, sleep disorders, and features of autism can also appear.⁴

The Genetic Cause and Why It Almost Always Comes from the Mother

Myotonic dystrophy type 1 is caused by a stretch of repeated DNA letters (CTG) in a gene called DMPK. Everyone carries a short run of these repeats, but when the number climbs into the hundreds or thousands, the gene’s messenger RNA becomes toxic to cells. In congenital cases, the repeat count is usually very large, often exceeding 1,000 copies.⁴ One of the disorder’s most striking features is that it is inherited almost exclusively from the mother. Fathers with myotonic dystrophy can pass on the gene, but their children almost never develop the congenital form.¹

The reason for this maternal bias is still being worked out, but a leading explanation involves chemical tags on the DNA surrounding the repeat expansion. Research has shown that methylation patterns flanking the CTG repeat differ between maternally and paternally inherited expansions, and that these methylation differences are associated with the congenital form of the disease.⁵ In other words, the size of the repeat matters, but so does the biological context in which it is passed on. A very large expansion from the father may still produce classic adult-onset disease, while a similarly large expansion from the mother is far more likely to cause the congenital form.

This pattern creates a difficult reality for families. Many mothers only discover they have myotonic dystrophy themselves after their baby is diagnosed with the congenital form. Their own symptoms may have been mild enough to go unrecognized for years.

What Happens Inside the Cell

The expanded CTG repeat in the DNA gets copied into RNA, producing long CUG repeat tracts in the messenger RNA. These abnormal RNA molecules fold into hairpin structures and accumulate in clumps inside the cell nucleus. They act like molecular sponges, trapping proteins that cells need for normal RNA processing. Two protein families are central to the problem: MBNL proteins get sequestered by the toxic RNA, and CELF1 proteins become overactive as a compensatory response.⁶

The downstream effect is a widespread disruption of how cells edit their RNA before turning it into protein. During normal development, cells switch from fetal versions of many proteins to adult versions. When MBNL proteins are trapped and unavailable, that switch stalls, leaving cells stuck using fetal protein forms that cannot support adult tissue function.⁶ In the brain specifically, MBNL2 binds directly to the expanded repeats, pulling it away from its normal RNA targets and disrupting both splicing and other processing steps.⁷ This helps explain why the congenital form affects so many organ systems at once. It is not just a muscle disease; the same toxic RNA mechanism operates in the brain, heart, and other tissues.

Signs Before Birth

Congenital myotonic dystrophy often leaves clues during pregnancy, though they are easy to attribute to other causes. The most consistent finding is polyhydramnios, an excess of amniotic fluid. In one review of affected pregnancies, every single case showed polyhydramnios.⁸ The excess fluid accumulates because the fetus swallows poorly, a direct consequence of weak facial and throat muscles. Other ultrasound findings include clubfoot (talipes), reduced fetal movement, and occasionally mild brain ventricle enlargement.⁹

The challenge is that polyhydramnios and reduced fetal movement have many possible causes, and myotonic dystrophy is not always on the radar. In one reported case, a 27-year-old woman with no known family history of the disease presented at 25 weeks with fetal akinesia and polyhydramnios. Standard genetic sequencing did not pick up the diagnosis because the CTG repeat expansion is not reliably detected by next-generation sequencing methods.¹⁰ That last point is important and often overlooked: many prenatal genetic tests, including common exome and genome sequencing panels, can miss myotonic dystrophy because the repeat expansion requires specialized testing to detect.

What Happens After Birth

The immediate newborn period is the most dangerous time. Babies with congenital myotonic dystrophy are typically born severely hypotonic, meaning their muscles have almost no resting tension. They have a characteristic facial appearance with a tented upper lip and an open mouth, and they often cannot breathe adequately on their own. A large review of 118 cases found that roughly six in ten required intubation and mechanical ventilation, a similar proportion had polyhydramnios noted before birth, and more than three-quarters needed feeding therapy. Neonatal death occurred in about 16% of cases.¹¹

The duration of ventilation appears to predict later outcomes. A study dividing babies into groups based on whether they needed more or fewer than 30 days of mechanical ventilation found that those with prolonged ventilation had a 25% mortality rate in the first year, while none of the babies ventilated for a shorter period died during that same window.¹² This does not mean 30 days is a magic number, but it gives families and clinicians a rough sense of trajectory. The longer a baby depends on a ventilator, the higher the risk that breathing problems will persist.

Getting the Diagnosis

Because congenital myotonic dystrophy is caused by a repeat expansion rather than a single-letter change in the DNA, it requires specific laboratory techniques to confirm. Standard approaches include specialized PCR methods and Southern blot analysis, which can measure the size of the CTG repeat.¹³ Routine genetic sequencing, the kind increasingly used in prenatal and neonatal settings, frequently misses this type of mutation because it was designed to detect smaller changes. This gap is a real source of delayed or missed diagnoses.

In practice, the quickest route to diagnosis often starts with the mother. If a baby presents with severe hypotonia and breathing failure, and the mother has any signs of myotonic dystrophy, even mild ones like difficulty releasing a handshake or cataracts at a young age, targeted genetic testing for the CTG repeat can confirm the diagnosis in both parent and child. Genetic counseling is recommended alongside testing, both for confirming the diagnosis and for discussing implications for future pregnancies.¹⁴

Growing Up with the Condition

Babies who survive the neonatal period generally show gradual improvement in muscle strength over the first few years of life. The severe floppiness of infancy gives way to better motor function, and many children learn to walk, though often later than their peers. However, the intellectual and behavioral challenges tend to become more apparent as children enter school. The most frequently reported long-term medical problems are recurrent respiratory infections, which remain the leading cause of illness throughout childhood.¹¹

Functional assessments paint a clear picture of ongoing disability. In one study comparing people with congenital myotonic dystrophy to healthy controls, the average distance covered in a six-minute walk test was about 258 meters versus 568 meters for controls, roughly half the distance. Grip strength, lip muscle force, and sleep quality were all significantly reduced as well.³ Children and young adults with the condition also face behavioral challenges and intellectual disability that can significantly affect how they participate in school, work, and social life.¹⁵

The transition from pediatric to adult care is particularly rocky. Many healthcare systems are not well set up to handle the complex, multi-system needs of young adults with congenital myotonic dystrophy, and families can find themselves falling between the gaps of childhood and adult services.

Day-to-Day Care and Monitoring

There is no cure for congenital myotonic dystrophy, so management focuses on supporting each affected organ system. Consensus care recommendations call for regular monitoring across multiple specialties.¹⁶ In practical terms, this usually includes:

Respiratory care: Ongoing assessment for sleep-disordered breathing, prompt treatment of chest infections, and in some cases overnight ventilatory support.
Feeding support: Many children need tube feeding in infancy, and some continue to need modified diets or feeding therapy for years.
Cardiac monitoring: Heart rhythm problems can develop even in childhood, so periodic ECGs and sometimes more detailed cardiac testing are standard.
Developmental support: Speech therapy, occupational therapy, physical therapy, and special education services form the backbone of developmental care.

Interviews with families affected by congenital and childhood myotonic dystrophy have identified communication difficulties, cognitive limitations, and restrictions on social participation as the symptoms with the greatest impact on quality of life. Researchers catalogued 189 distinct symptoms across 22 themes spanning physical, emotional, social, and disease-specific categories, some of which had been previously under-recognized by clinicians.¹⁷ That breadth of symptoms underscores why coordinated, multidisciplinary care matters so much for these families.

Anesthesia and Surgical Risks

Any child or adult with myotonic dystrophy who needs surgery faces specific risks from anesthesia. People with the condition can react unpredictably to sedatives, muscle relaxants, and inhaled anesthetics, sometimes experiencing prolonged muscle contractions, dangerous drops in respiratory function, or cardiac complications.¹⁸ This is not a theoretical concern. The sensitivity is real enough that anesthesiologists need advance notice and a tailored plan whenever a person with the diagnosis goes to the operating room. Families should make sure this information is part of the medical record and flagged for any surgical team.

Family Planning Options

Because the CTG repeat tends to expand further with each generation, a parent with myotonic dystrophy, especially a mother, faces a meaningful risk of having a child with the congenital form. Genetic counseling can help families understand these risks. For those who want to reduce the chance of passing on a large expansion, preimplantation genetic diagnosis is an established option. This involves creating embryos through IVF and testing them for the repeat expansion before transfer. Reports from the UK describe it as a practical option for affected couples.¹⁹ Prenatal testing through chorionic villus sampling or amniocentesis is also available for pregnancies already underway.

Pregnancy itself carries additional risks for women with myotonic dystrophy. Careful assessment for cardiac, obstetric, and anesthesia-related complications is important, and these pregnancies benefit from management at centers experienced with the condition.²⁰

Research into Future Treatments

Because the disease mechanism is well understood at the molecular level, researchers have several promising angles of attack. Gene therapy approaches aim to reduce or eliminate either the expanded CTG repeats or the toxic RNA they produce. One strategy uses CRISPR-based tools not to cut the DNA but to silence the DMPK gene’s promoter, effectively turning down the volume on the toxic transcript. A proof-of-concept study showed that this approach reduced toxic CUG-repeat RNA levels by up to 80% in cell models.²¹

A broad pipeline of RNA-targeting therapies is also in development, including antisense oligonucleotides designed to break up or degrade the toxic RNA, along with newer delivery methods using peptide conjugates to help these molecules reach skeletal and heart muscle more effectively.²² None of these therapies are available clinically yet, and the jump from cell culture to a safe, effective treatment in a living person is large. Still, the fact that the toxic RNA mechanism is well characterized gives researchers a clear target, which is more than many genetic diseases can claim.

A Rare Congenital Form in Type 2

Nearly all discussion of congenital myotonic dystrophy refers to type 1, and for good reason: type 2, caused by a different repeat expansion in a different gene, very rarely presents at birth. However, a handful of cases have been reported. Like the type 1 form, congenital type 2 has been transmitted exclusively by the mother in the cases described so far, suggesting a parallel maternal bias mechanism.²³ These cases are rare enough that most clinicians will never encounter one, but their existence is a reminder that the biology of repeat expansion diseases continues to surprise researchers.

What Muscle Biopsies Show

When muscle tissue from babies with congenital myotonic dystrophy is examined under a microscope, the findings are often nonspecific. A study of biopsies taken during the first year of life found changes like uneven muscle fiber sizes and selective shrinkage of certain fiber types, but nothing unique enough to make the diagnosis on its own.²⁴ Earlier descriptions had suggested that a “maturational arrest” of the muscle, where fibers appear stuck at an immature stage, was a defining feature. The biopsy evidence suggests this is not always present. In practical terms, muscle biopsy has largely been replaced by genetic testing as the primary diagnostic tool, since DNA analysis is faster, less invasive, and definitive.

1
PubMed. Molecular genetics of congenital myotonic dystrophy
2
PubMed. Congenital myotonic dystrophy. Incidence, clinical aspects and early prognosis
3
PubMed Central. Disease burden and functional outcomes in congenital myotonic dystrophy: A cross-sectional study
4
Frontiers in Cellular Neuroscience. Cognitive impairment, neuroimaging abnormalities, and their correlations in myotonic dystrophy: a comprehensive review
5
American Journal of Human Genetics. DNA Methylation Flanking the Expanded CTG Repeat at the DM1 Locus Causes Congenital Myotonic Dystrophy and Is Associated with Maternal Transmission Bias
6
PubMed Central. An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
7
PubMed Central. MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain
8
PubMed. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome
9
PubMed Central. Case report of congenital myotonic dystrophy with multiple prenatal sonographic findings
10
PubMed. Congenital myotonic dystrophy: An overlooked diagnosis not amenable to detection by sequencing
11
PubMed. Prenatal, Neonatal, and Early Childhood Features in Congenital Myotonic Dystrophy
12
Pediatrics. Congenital Myotonic Dystrophy: Assisted Ventilation Duration and Outcome
13
PubMed Central. Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG)
14
PubMed Central. Molecular genetics and genetic testing in myotonic dystrophy type 1
15
PubMed Central. Hard ways towards adulthood: the transition phase in young people with myotonic dystrophy
16
PubMed Central. Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1
17
PubMed. The impact of congenital and childhood myotonic dystrophy on quality of life: a qualitative study of associated symptoms
18
PubMed Central. Anesthetic Considerations in a Patient with Myotonic Dystrophy for Hip Labral Repair
19
PubMed. Preimplantation genetic diagnosis for myotonic dystrophy type 1 in the UK
20
PubMed Central. Preimplantation genetic diagnosis for myotonic dystrophy type 1: upon request to child
21
Molecular Therapy Nucleic Acids. DMPK-promoter silencing by CRISPR interference as a novel therapeutic approach for myotonic dystrophy type 1
22
PubMed. Therapeutic Strategies Targeting the Molecular Pathogenesis of Myotonic Dystrophy Type 1: Current Status and Future Directions
23
PubMed. Child Neurology: Maternal Transmission of Congenital Myotonic Dystrophy Type 2: Case Report
24
PubMed Central. Skeletal muscle in children with congenital myotonic dystrophy in the first year of life